218 results about "Levorotatory" patented technology

The invention relates to a levo-oxiracetam slow-release tablet mainly prepared from levo-oxiracetam, which is prepared from the following raw and auxiliary materials in parts by weight: 0.8-1.2 parts of slow-release framework material, 0.06-0.12 part of flow aid, 0.02-0.05 part of lubricant, 0.02-0.05 part of antisticking agent and 1-1.5 parts of adhesive. The levo-oxiracetam slow-release tablet is used for treating brain injury, and neural afunction and disturbance of memory and intelligence caused by brain injury, and has a smooth surface; the detection proves that the release behavior of the main drug levo-oxiracetam satisfies the requirements for the slow-release tablet; and the main drug levo-oxiracetam is slowly released, so the levo-oxiracetam slow-release tablet can be taken less frequently than the traditional preparation. The main drug levo-oxiracetam in the levo-oxiracetam slow-release tablet is slowly released, and can provide steady and enduring effective blood concentration, thereby avoiding or reducing the phenomena of peaks and troughs of blood concentration, and being beneficial to enhancing the medicine application safety and reducing the untoward reaction of the medicine.

The invention relates to a method for preparing a nanofiber bracket material using levorotatory polylactic acid as matrix. The method comprises the following steps: dissolving the levorotatory polylactic acid as the matrix in a solution of dichloromethane and dimethyl formamide, and stirring and centrifuging the mixture to obtain an electrostatic spinning solution; placing a polylactic acid solution into a 5 milliliter glass syringe, and applying high voltage on the glass syringe; advancing the levorotatory polylactic acid solution in the glass syringe; preparing the mixed solution into a nanofiber material film through a electrostatic spinning technology; and modifying the nanofiber material film to obtain the nanofiber bracket material of which the fiber diameter is between 50 and 500 nanometers and the fiber porosity is more than 90 percent. The method solves the defects that a PLLA porous bracket still has too long degradation time, and degradation products can cause tissue inflammations easily and the like. The method has the advantages of flexible texture, better water permeability and air permeability, excellent tissue compatibility, controllable biodegradability, and no antigenicity.

The invention relates to application of levorotatory oxiracetamto to the field of pharmacy, and specifically relates to application of levorotatory oxiracetamto preparation of medicaments for preventing or treating cognitive dysfunction. According to the invention, levorotatory oxiracetamto with a purity higher than 99.3% is used as a material, so that hidden trouble of drug toxicity caused by invalid ingredients in a medicament is eliminated to further ensure medications safety. In addition, levorotatory oxiracetamto is a single active ingredient in the medicament of the invention, so that medicament quality is easier to control, and a curative effect is more obvious.

The invention discloses a carbon nanotube / polylactic acid conductive composite material and a preparation method; the conductive composite material comprises the following blended components: levorotatory polylactic acid resin, and dextrorotatory polylactic acid resin, carbon nanotube and an anti-oxidant; the using amount of the carbon nanotube is 0.2-3 parts by weight; the weight ratio of the levorotatory polylactic acid resin and the dextrorotatory polylactic acid resin is (80-50):(20-50). The method comprises the following steps: performing melt blending of the levorotatory polylactic acid resin, the carbon nanotube, and the anti-oxidant according to the using amounts to prepare a master batch, then performing melt blending with the dextrorotatory polylactic acid resin to prepare the carbon nanotube / polylactic acid conductive composite material. The conductive composite material of the invention is added with a few CNTs, and thus the material is provided with good conductivity; the conductive percolation threshold is significantly reduced to 0.5 wt%; the operation process is simple, and is suitable for continuous mass production.

The invention relates to a synthetic method for L-type glufosinate ammonium. The synthetic method includes the steps that 4-(oxethyl-(methyl) phosphinyl)-2-acetoxyl butyl cyanide and hydrochloric acid react to obtain 4-(hydroxyl-(methyl) phosphinyl)-2-hydroxybutyric acid; 4-(hydroxyl-(methyl) phosphinyl)-2-hydroxybutyric acid reacts with a sodium hydroxide water solution to obtain 4-(sodium hydroxyl-(methyl) phosphinyl)-2-sodium hydroxyl butyrate; 4-(sodium hydroxyl-(methyl) phosphinyl)-2-sodium hydroxyl butyrate reacts with a sodium hypochlorite water solution to obtain 4-(sodium hydroxyl-(methyl) phosphinyl)-2-sodium carbonyl butyrate; 4-(sodium hydroxyl-(methyl) phosphinyl)-2-sodium carbonyl butyrate reacts with hydrogen chloride gas to obtain 4-(hydroxyl-(methyl) phosphinyl)-2-carbonyl butyric acid; 4-(hydroxyl-(methyl) phosphinyl)-2-carbonyl butyric acid reacts with liquid ammonia, and then hydrogen is introduced for reacting to obtain L-type glufosinate ammonium. The synthetic method is simple in technical process, small in pollution, high in yield and low in cost, the obtained finished product is levorotatory glufosinate ammonium with the efficient weeding effect, and the weeding effect of glufosinate ammonium is greatly improved.

The invention relates to a high precision GNSS receiver, which comprises a levorotatory and dextrorotary circular polarization antenna, a first radio frequency front end module and a second radio frequency front end module with a local clock, a signal following module and a CPU. The signal following module comprises a satellite capturing unit, a first satellite following unit, a second satellite following unit and an interface unit. A capturing control module, a text demodulation module, two loop following modules, two initial data measuring modules, an availability choosing module, a position resolving module and an interface protocol module are arranged in the CPU. The availability choosing module obtains the pseudo range and the carrier-to-noise ratio data of levorotatory signals and dextrorotary signals, analyzes and chooses the weak initial data of multipath signals and transmits to the position resolving module for final position resolving. The invention compares and analyzes the levorotatory signals and the dextrorotary signals, alleviates the multipath influence on data source, ensures the GNSS receiver obtains high position precision, can improve the multipath influence alleviating effect based on the traditional multipath alleviating technology, has strong structural expansibility and can realize flexible framework configuration.

The invention discloses a high-heat-resistance high-strength polylactic acid / inorganic fiber composite material or product. Firstly, dextrorotatory polylactic acid or levorotatory polylactic acid is grafted on an inorganic fiber surface, and subsequently the polylactic acid / inorganic fiber composite material or product can be obtained by stereocomplexing of the inorganic fiber surface and a base molecular chain of the dextrorotatory polylactic acid or levorotatory polylactic acid in an interface region by means of melt-mixing, wherein the degree of crystallinity of the material or product is 45.5% to 48.7%, the content of inorganic fibers is 0.2wt% to 5.0wt%, the tensile strength is 49.3Mpa to 55.8MPa, and the heat resisting temperature is 138.4 to 150.2 DEG C. According to the method disclosed by the invention, by utilizing the characteristic that the polylactic acid has chiral molecules, the dextrorotatory polylactic acid or levorotatory polylactic acid grafted on the inorganic fiber surface and a stereocomplex crystal formed by the dextrorotatory polylactic acid base body or levorotatory polylactic acid base body in the interface region are used for synchronously realizing interface reinforcement and high-efficiency nucleation effect on the base body, so the method is ingenious in design and provides an effective and simple way for developing the high-heat-resistance high-strength polylactic acid composite material or product.

The invention relates to a combination of atorvastatin and levamlodipine, mainly consists of levamlodipine or officinal salt thereof, atorvastatin or officinal salt thereof, alkali metal salt, and cyclodextrin and derivatives thereof and guarantees the stability and the bioavailability of atorvastatin and levamlodipine.

The invention discloses a preparation method of photo-response type chirality intelligent nanometer particles. The preparation method is characterized by comprising the following steps of: preparing a trichloromethane solution with a repetitive unit concentration of 3*10<-2> mg / mL from a 9,9-dioctylfluorene-azobenzene alternating copolymer, wherein Mn in the 9,9-dioctylfluorene-azobenzene alternating copolymer is equal to 7770 g / mol and the ratio of Mw to Mn is equal to 2.62; uniformly mixing the solution with alcohol the volume of which is the same as that of the solution; and irradiating the mixture for 1-30 minutes by using levorotatory or dextrotatory polarized light so as to obtain left-handed helix or right-handed helix chirality nanometer particles. By using the preparation method provided by the invention, the problems that when the traditional method is adopted to synthesize the polymer chirality intelligent nanometer particles, a chiral reagent is expensive, synthetic steps are complex and the like are solved; the obtained product is alternatively irradiated by the levorotatory or dextrorotatory polarized light, thus the chiral spiral direction of the nanometer particles can be changed, so as to present the good properties of a photo switch.

The invention discloses a method for obtaining levorotatory enantiomer and dexiotropic enantiomer by separation from medetomidine (chemical name: 4-(1-(2,3-dimethylphenyl)-ethyl)-1H-imidazole) of racemate, which comprises the steps of reacting medetomidine racemate with optically active acid so that medetomidine racemate can be converted into salts of diastereoisomer, and then separating the saltsof the diastereoisomer by using a half-dose resolution method so as to obtain single enantiomer with particular optical purity.

The invention relates to a foldable work light. The foldable work light comprises a main body of the foldable work light and a battery, a first light-emitting part, a circuit board and a switch which are mounted in the main body. The foldable work light is characterized in that: the foldable work light is further provided with a levorotatory component and a dextrorotatory component; the levorotatory component and the dextrorotatory component are rotationally connected onto the main body; a second light-emitting part is arranged in the levorotatory component and the dextrorotatory component respectively; a light-transmitting shade which enables the light of one second light-emitting part to transmit is also arranged at a side face of the levorotatory component and a side face of the dextrorotatory component respectively; and the second light-emitting parts compose a light-emitting circuit with the battery, the circuit board and the switch in the main body through connecting wires. The foldable work light has the advantages of compact and reasonable structure, a plurality of light sources, capability of being rotated and folded, stableness in supporting and the like.

The invention belongs to a static pressure measurement calibration instrument, and in particular relates to a gas pressure regulator which is designed by a new principle, and a gas pressure regulation method. The gas pressure regulator comprises a regulator main body, a transmission part, a piston assembly, a combination valve and a sealing piece. In the invention, mass regulation and capacity regulation are combined with each other, and the advantages of a mass gas pressure regulation method and a capacity gas pressure regulation method are combined together, so that higher control speed andhigher control accuracy can be realized by pressure regulation from a low range to a high range. The method comprises the following steps of: coarsely regulating a target pressure value in a mass gaspressure regulation mode and finely regulating the target pressure value in a capacity gas pressure regulation mode, namely increasing or reducing the mass of gas simultaneously for a front cavity and a rear cavity of the pressure regulator through the combination valve so as to make the target pressure value of the regulator coarsely realized; and driving a piston on a nut actuator to move back and forth in a main body cavity through a levorotatory guide screw rod and finely regulating to acquire the target pressure value.

The invention discloses a bactericide composition containing difenoconazole and levorotatory alpha-terpineol. The bactericide composition is characterized by comprising effective components of 1% to 50% by weight of difenoconazole and 1% to 50% by weight of levorotatory alpha-terpineol, and is mainly used for preventing and treating sigatoka. The invention has the advantages of obvious synergy function after formulation, obvious reduction of the usage amount and the usage frequency of the bactericide, lower cost and drug resistance of plant disease deferment. Meanwhile, the levorotatory terpineol as monoterpene alcohols prepared by compounding natural renewable resources can be degraded easily in environment, and meets environment friendly requirement. Moreover, micro-emulsion and aqueous emulsion relevant to the invention replace organic solvent with water portion, and environment pollution is reduced as well.

The invention relates to levorotatory isovaleryl spiramycin III, and also relates to a preparation, a preparation method and application thereof. The preparation consists of the levorotatory isovaleryl spiramycin III and a pharmaceutically acceptable carrier and / or auxiliary materials, and the purity of the levorotatory isovaleryl spiramycin III is over 90 weight percent, preferably over 95 weight percent and further preferably over 98 weight percent. The levorotatory isovaleryl spiramycin III has good antibacterial activity; the preparation of the levorotatory isovaleryl spiramycin III comprises water injection for injection, powder injection for injection and freeze-dried powder injection, fills up a blank of a single-component preparation of the isovaleryl spiramycin III in the current market and provides a new quick-response way for treating infectious diseases. The single-component preparation of the isovaleryl spiramycin III has the advantages of stable production process, easily controlled quality standard, and suitability for large-scale industrial production.

A multilayered cholesteric liquid crystal which comprises at least one light reflection layer (Xa) that is a light reflection layer obtained by fixing a cholesteric liquid-crystal phase and that contains a dextrorotatory chiral agent having an HTP of 30 μm-1 or more and at least one light reflection layer (Xb) that is a light reflection layer obtained by fixing a cholesteric liquid-crystal phase and that contains a levorotatory chiral agent having an HTP of 30 μm-1 or more, all of the light reflection layers (Xa) and all of the light reflection layers (Xb) having a selective-reflection wavelength in the range of 400-750 nm and the selective-reflection wavelength of at least one of the light reflection layers (Xa) being equal to the selective-reflection wavelength of at least one of the light reflection layers (Xb), and in which all the adjoining light reflection layers obtained by fixing a cholesteric liquid-crystal phase have been superposed so as to be in contact with each other. In the multilayered cholesteric liquid crystal, dextrorotatory and levorotatory, inversely twisted, cholesteric liquid-crystal layers have been superposed so as to be in contact with each other without using a pressure-sensitive adhesive therebetween. This multilayered cholesteric liquid crystal has good surface properties and high transparency, selectively reflects light in the visible-light region, and has high reflection performance.

The invention discloses bornyl ferulate. The bornyl ferulate and a pharmaceutically acceptable prodrug are applied to pharmacy; the bornyl ferulate is applied to treatment of cerebrovascular diseases; the bornyl ferulate comprises two structures including dextral bornyl ferulate and levorotatory bornyl ferulate; the structure formula of the dextral bornyl ferulate is shown as the specification; the structure formula of the levorotatory bornyl ferulate is shown as the specification; the dextral bornyl ferulate is an enantiomer of the levorotatory bornyl ferulate. A synthesis process of the bornyl ferulate is simple and short; raw materials are easy to obtain and are toxin-free and harmless; the synthesis process is easy to control; no harmful products are generated; the synthesis process is an environment-friendly and economical process and can be widely applied to the production of medicines for treating the cerebrovascular diseases.

The invention relates to a pipe connection structure of a conductor pipe in an RF cable. The tube can be processed to a needed length by the connection structure and the signal transmission quality is good. The pipe connection structure of a conductor pipe in a RF cable comprises copper cladding aluminum pipe sections. The pipe connection structure of a conductor pipe in a RF cable is characterized in that the two ends of the pipe section are respectively processed with a levorotatory inner thread and a dextrogyrate inner thread; the copper cladding aluminum pipe sections are connected by a double-head levorotatory bidirectional screwed conduit joint and a double-head dextrogyrate bidirectional screwed conduit joint to form a long pipe; the copper pipes of neighboring pipe sections are welded and connected at the locations of the joints.

The invention relates to the technical field of medicines, in particular discloses a levorotatory fluoroquinolone C3 diazole methyl sulfide quaternary ammonium salt, and further discloses a preparation method and application of the levorotatory fluoroquinolone C3 diazole methyl sulfide quaternary ammonium salt in the pharmaceutical field simultaneously. The chemical structural formula of the levorotatory fluoroquinolone C3 diazole methyl sulfide quaternary ammonium salt is represented by a general formula I: the general formula I is described in the specification. The levorotatory fluoroquinolone C3 diazole methyl sulfide quaternary ammonium salt provided by the invention has stronger in-vitro cytotoxicity effect on experimental leukemia cancer cell strains and stronger anti-tumor activity, and can be mixedly prepared into anti-tumor medicines with human body acceptable acidic salts or pharmaceutical carriers.

A film clamping device for double-film pressure-fixed film breaking and single-film impact film breaking relates to the field of high-supersonic-speed shock-wave wind tunnel engineering. The fill clamping device a levorotatory screw, a Laval nozzle, an open-mounted nut, a first adjusting ring and a gas vent; a through hole is arranged horizontally in the middle portion of the open-mouthed nut; the first adjusting ring is vertically and fixedly mounted at one end of the through hole of the open-mounted nut; the Laval nozzle is fixedly mounted in the external surface of the first adjusting ring along the axial direction of the through hole of the open-mounted nut; the levorotatory screw is fixedly mounted in the external surface of the first adjusting ring along the axial direction of the through hole of the open-mounted nut, and wraps the Laval nozzle; and the gas vent is arranged in the top of the open-mounted nut along the vertical direction, and is communicated with the upper surface of the open-mounted nut and the through hole in the middle of the open-mounted nut. Energy is transmitted from one end to the other end of a film rapidly during operation of a wind tunnel in a film breaking manner, especially the film clamping device can realize double-film pressure-fixed film breaking and single-film impact film breaking, and thus, different conditions of wind tunnel operation can be met at the same time.

The invention provides a capsule with the effect of weight reducing and a preparation technology thereof. The capsule is prepared from the following components by weight percent: 68-78% of levorotatory carnitine tartrate and 22-32% of tea polyphenol. The invention has the advantages that the whole formula has proficient material use, low production cost and obvious effect, and the invention has the effects of prompting fat metabolism, regulating protein degradation, suppressing the absorption of an organism to saccharide and preventing sugar from being transformed into fat, is suitable for a fat patient and has simple processing method, low cost, convenient taking and no adverse reaction.

The invention relates to a wig softener which is formed by selecting a reagent material and used for softening a wig product, a preparation process thereof and a method for arranging the wig product. The wig softener consists of the following raw materials in percentage by weight: 6 to 8 percent of hexadecyl trimethyl ammonium chloride, 6 to 9 percent of carboxymethylcellulose, 0.1 to 0.4 percentof sodium sulfate solution with the sodium sulfate concentration of 2 percent, 0.3 to 0.6 percent of levorotatory menthol solution with the levorotatory menthol concentration of 3 percent, 0.5 to 2 percent of higher fatty alcohol polyoxyethylene ether solution with the higher fatty alcohol polyoxyethylene ether concentration of 3 percent, 0.1 to 0.4 percent of sodium silicate solution with the sodium silicate concentration of 25 percent, and 80 to 86 percent of deionized water. The wig softener has the advantages of antibiosis and anti-ultraviolet functions, nontoxicity, no stimulation, high washability and simple manufacturing process.

The invention discloses a stepless regulation device for a gap between a compression roller and a ring die, comprising an elastic clamping tumbler fixedly connected to a main shaft, wherein the elastic clamping tumbler is symmetrically provided with two compression roller assemblies; the front ends of the two compression roller assemblies are provided with junction plates fixed by levorotatory round nuts; the middle of each junction plate is provided with a tension stud connected with the elastic clamping tumbler; the middle of the elastic clamping tumbler is rectangular; two sides of the elastic clamping tumbler are in reverse symmetric arc shape; the middle of the elastic clamping tumbler is provided with a center hole matched with a main shaft key; two sides of the center hole are symmetrically provided with two side holes respectively matched with the two compression roller assemblies; one side of the two side holes, which is near the direction of the arc shape, is respectively provided with a gap; and a plane vertical to the gap is provided with an inner hexagon screw. The stepless regulation device has simple structure, can realize the purpose of the stepless regulation of the gap, is convenient to regulate the gap between the compression roller and the ring die and is practical and reliable.

The invention relates to a method for splitting a chiral medicine of hydrochloric acid lomefloxacin, adopting a high-speed counter-current chromatography method to separate out levorotatory hydrochloric acid lomefloxacin and dextrorotatory hydrochloric acid lomefloxacin from a hydrochloric acid lomefloxacin crude extract. A solvent system comprises three components of ethers or normal paraffin hydrocarbon or fatty ester, acetonitrile or fatty alcohol or fatty ketone and water, the volume ratio is sequentially 5-100:1:5-100, an upper phase is used as a stationary phase, a lower phase is used as a flowing phase, sulphonation-beta-schardinger dextrin is used as a chiral splitting reagent, the content of the sulphonation-beta-schardinger dextrin in the lower phase is 0.02-0.06mol / L, and a chiral flowing phase method is adopted to split a hydrochloric acid lomefloxacin enantiomorph. The method for splitting the chiral medicine of the hydrochloric acid lomefloxacin can achieve higher separating degree, is suitable for various types of prepared type counter-current chromatography instruments and can separate and obtain the monomers of the levorotatory hydrochloric acid lomefloxacin and the dextrorotatory hydrochloric acid lomefloxacin.

The invention belongs to the pharmaceutical field, and relates to a purifying method of levorotatory borneol. The invention discloses a preparation method of high-purity levorotatory borneol. The method comprises the following steps: performing centrifuge dripping on marketed crude levorotatory borneol (the content of levorotatory borneol is about 65%), dissolving in a reagent A, then, adding a reagent B into the liquor, and reacting for a certain time at a certain temperature; then pouring into water, standing and filtering; and recrystallizing by use of a reagent C for the filter cakes and drying to obtain the high-purity levorotatory borneol.

The invention relates to the technical field of injection facial fillers, in particular to polylactic acid microspheres and a preparation method and application thereof. The preparation method comprises the following steps: A) mixing polylactic acid and a solvent to obtain a polylactic acid solution, wherein the polylactic acid comprises levorotatory polylactic acid, dextrorotatory polylactic acidor meso-polylactic acid, and the solvent comprises dichloromethane; B) mixing the polylactic acid solution and a polyvinyl alcohol solution, and carrying out high-speed shearing under an ice bath condition to obtain an emulsion; and C) mixing the emulsion with water, removing the solvent, and then freeze-drying to obtain the polylactic acid microspheres. The polylactic acid microspheres are prepared from polylactic acids with different chiralities as raw materials, and the obtained microspheres are smooth in surface, small and uniform in particle size, easy to inject, easy to disperse and small in adverse reaction when used as facial fillers. In addition, the preparation method of the polylactic acid microspheres is simple and convenient, and industrial production is easy to implement.

The process of preparing levosalbutamol hydrochloride with racemoid salbutamol as material includes the following steps: dewatering racemoid salbutamol in acetone to obtain compound I, resolving compound I with optically pure organic acid A in solvent of water consolute fatty alcohol to obtain compound II, dissociating compound II under the action of alkali to obtain compound III, deprotecting compound III in HCl solution to form salt, and refining to obtain levosalbutamol hydrochloride. The process of the present invention has facile material, simple operation and short reaction period, and is simple and suitable for industrial production.

The invention relates to an application of amlodipine to the preparation of medicaments for curing phoproliferative diseases. The amlodipine is selected from racemic amlodipine, levorotatory amlodipine and pharmaceutically acceptable salts, and the phoproliferative diseases particularly refer to various malignant tumors, such as leukemia, lung cancer, gastric cancer, liver cancer, ovarian cancer, prostatic cancer, cervical cancer, breast cancer and squamous carcinoma.

The invention provides an anti-platelet aggregation optically active polypeptide compound. The compound consists of three amino acids, namely levorotatory or dextrorotatory tryptophan, asparagine and pyroglutamic acid, and is used for treating platelet aggregation-related heart cerebrovascular diseases, such as ischemic stroke, inflammation, asthma and the like.

The invention discloses a polylactic acid membrane which comprises the following components in percentage by weight: 80-95wt% of polylactic acid and 5-20wt% of a polyester fiber, wherein the polylactic acid is selected from at least one of a levorotatory polylactic acid resin and a dextrorotatory polylactic acid resin; the melting index of the polylactic acid is 10-50g / 10 minutes; the testing condition is that testing is carried out with a load of 2.16Kg at 190 DEG C; the polyester fiber is selected from one of a polyterephthalic acid propylene glycol ester fiber or polyterephthalic acid butanediol ester fiber. The polylactic acid membrane disclosed by the invention is of a cross crystal structure, and has excellent longitudinal tension strength and excellent transverse tension strength aswell. The invention further discloses a preparation method of polylactic acid. The polyester fiber is adopted as a nucleating agent, and the cross crystal structure is directly prepared in a one-waymelt tension fluid field by using a melt tension technique. Relatively high transverse tension strength can be achieved when transverse tension is not carried out, and meanwhile a relatively high crystallization degree can be achieved for the polylactic acid in the melt tension process.